OKTO Ophtho to Exhibit at the American Academy of Ophthalmology Meeting in Anaheim

In addition to exhibiting at the main exhibit hall on November 15^th through 18^th, OKTO will also present its technologies at the American Academy of Oculoplastic and Reconstructive Surgeons (ASOPRS) and the "Under Pressure" Glaucoma meetings on November 13^th and 14^th.

OKTO's state-of-the-art, multi-media exhibit will display its core technologies for eye surgery: AmbioDry™ Amniotic Membrane Allografts and SutureGroove™ Gold Eyelid Weight Implants

AmbioDry Allografts, processed tissue grafts derived from human placenta, are employed by eye surgeons for the treatment of a variety of ocular surface disorders and defects. AmbioDry Allografts are procured, tested and processed in the United States.

In comparison to competitive tissue options, the advantages of the AmbioDry are vast: decellularized, sterile tissue matrix; shelf-life storage; prepares in minutes for surgery; substrate-free; consistent tissue quality.

SutureGroove Gold Eyelid Weights are employed by oculoplastic surgeons for the treatment of lagophthalmos. The proprietary SutureGroove technology, licensed by OKTO from AMI, incorporates suture fixation channels within the gold weight for perfected implant placement and improved patient cosmesis.

About OKTO

Founded in 2000, OKTO Ophtho develops and commercializes specialized, leading-edge surgical technologies for eye surgery. OKTO’s purpose is to develop surgical solutions that improve the quality of life for patients, elevate the performance and productivity of eye care professionals, and lower costs to the provider.

OKTO currently holds leadership positions with surgical devices for oculoplastic surgeries and bio-implant technologies for ocular surface/ophthalmic reconstructive surgeries.

Media Contact:

pr@oktoophtho.com